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Pharmaceuticals Exposed to the Space Environment: 
Problems and Prospects 
 
Donald A. Jaworske* and Jerry G. Myers 
National Aeronautics and Space Administration 
Glenn Research Center 
Cleveland, Ohio 44135 
Abstract 
The NASA Human Research Program (HRP) Health Countermeasures Element maintains ongoing 
efforts to inform detailed risks, gaps, and further questions associated with the use of pharmaceuticals in 
space. Most recently, the Pharmacology Risk Report, released in 2010, illustrates the problems associated 
with maintaining pharmaceutical efficacy. Since the report, one key publication includes evaluation of 
pharmaceutical products stored on the International Space Station (ISS). This study shows that selected 
pharmaceuticals on ISS have a shorter shelf-life in space than corresponding terrestrial controls. The HRP 
Human Research Roadmap for planetary exploration identifies the risk of ineffective or toxic medications 
due to long-term storage during missions to Mars. The roadmap also identifies the need to understand and 
predict how pharmaceuticals will behave when exposed to radiation for long durations. Terrestrial studies 
of returned samples offer a start for predictive modeling. This paper shows that pharmaceuticals returned 
to Earth for post-flight analyses are amenable to a Weibull distribution analysis in order to support 
probabilistic risk assessment modeling. The paper also considers the prospect of passive payloads of key 
pharmaceuticals on sample return missions outside of Earth’s magnetic field to gather additional statistics. 
Ongoing work in radiation chemistry suggests possible mitigation strategies where future work could be 
done at cryogenic temperatures to explore methods for preserving the strength of pharmaceuticals in the 
space radiation environment, perhaps one day leading to an architecture where pharmaceuticals are 
cached on the Martian surface and preserved cryogenically. 
Introduction 
Human space missions require pharmaceuticals to address crew health issues. Pharmaceuticals stored 
on the International Space Station (ISS) exhibit a shorter shelf-life in space than corresponding terrestrial 
controls; and radiation is thought to be as a possible cause (Ref. 1). The Pharmacology Risk Report by the 
Human Research Program (HRP) Human Health Countermeasures Element discusses the concern over 
pharmaceutical durability in terms of risks and gaps (Ref. 2). Given the report findings, the risk involves a 
“risk of therapeutic failure due to ineffectiveness of medication” caused by exposure to deep space 
radiation. The knowledge gap encompassing the risk states: “What is the effect of long-term spaceflight 
on drug stability and what measures can be employed to extend the duration of drug efficacy?” The HRP 
Requirements Document identifies the Human Spaceflight Risk of “Medications Long-Term Storage” for 
deep space journey/habitation as a high consequence that requires mitigation (Ref. 3). The HRP Human 
Research Roadmap for planetary exploration includes a “Risk of Ineffective or Toxic Medications Due to 
Long-Term Storage (Ref. 4).” 
This paper discusses the problems and prospects for pharmaceuticals exposed to the deep space 
environment. The first part of the paper discusses the active ingredient strength observed in the 
pharmaceutical inventory contained in the terrestrially administered Shelf Life Extension Program (SLEP) 
conducted by the Food and Drug Administration (Ref. 5). The US Pharmacopia specifies that the active 
ingredient must retain at least 90 percent of its labeled potency or strength, defined as the active ingredient 
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concentration. Chromatography, spectroscopy, and various other analytical techniques were used to assay 
the active ingredients in the SLEP study. The study considered other failure modes including appearance, 
pH, impurities, and in some cases mechanical failure of the delivery system. The SLEP study prompts a 
discussion suggesting that some pharmaceuticals may be sufficiently robust for long-term space flight while 
others may suffer from the loss of active ingredients, the generation of toxic substances, or an alteration in 
excipient characteristics. The next part of the paper summarizes research done on pharmaceuticals flown on 
ISS and returned to Earth for post-flight analyses. Not surprisingly, given the premium of return mass and 
volume, there exists only a few cases where specimens with space exposures have been returned to Earth to 
gather post-flight data. Wotring reports a retrospective study of pharmaceuticals use by astronauts, where in 
most cases efficacy was thought to be “somewhat to very effective (Ref. 6).” Du, et al., describe the physical 
and chemical changes of 35 different pharmaceuticals flown in kits on ISS over an 880 day test period (Ref. 
1). Four analogous kits remained on the ground as controls. The Wotring and Du studies prompt a 
discussion suggesting that some pharmaceuticals may be robust during long-term spaceflight while others 
may not. These evidence-based studies are derived from space flight exposures in the low Earth orbit 
environment. Extrapolating their findings to long-term space flights outside of Earth’s magnetic field is 
considered both a problem and a prospect. In addition, a discussion of the Du data provided in the context of 
Weibull statistics illustrates their usefulness in probabilistic risk assessment modeling. The third part of this 
paper discusses recent work in radiation chemistry. 
Terrestrial and Orbital Studies of Pharmaceutical Durability 
One objective of the system integration process is to estimate mission risk by estimating the risks of 
constituent parts, and summing the risks to obtain an overall mission risk. One of the risks of greatest 
concern is that of astronaut health—specifically ill health brought on by insomnia, pain, headaches, 
gastro-intestinal discomfort, and infection. Pharmaceuticals are available on ISS to treat such conditions. 
A similar inventory of pharmaceuticals is expected to be included for missions to Mars. Several studies 
address the durability of pharmaceuticals. Reviewing these studies provides a means to understand the 
problems and prospects of pharmaceutical durability in long duration deep space missions. 
The Terrestrial SLEP Study 
The Food and Drug Administration conducted a terrestrial study to evaluate pharmaceuticals that 
were stored beyond their original expiration date based on a comprehensive testing program (Ref. 5). The 
study summarized the long-term stability of 122 drug products stored in their original containers and 
evaluated beyond their labeled expiration date. Interpretation of the data was accomplished by arranging 
the pharmaceuticals into five groups based on their dosage form. In general the findings showed that solid 
oral products exhibited the greatest longevity, whereas liquids exhibited the least longevity—suffering 
from numerous failure mechanisms. Creams and ointments exhibited mixed longevity results. 
Tests were performed on the pharmaceuticals based on their attributes. Potency was evaluated for all 
products by conducting active ingredient assays. Regression analyses of real-time assay data determined 
if shelf life extensions were granted or if no shelf life extensions were granted. A termination failure 
occurred when a pharmaceutical already granted an extension could not be granted any further extensions. 
An assay value dropping below 90 percent of the stated active ingredient was sufficient to trigger a 
termination failure. The solid oral products, reconstituted dry powders, creams and ointments, injectable 
solutions, and autoinjectors were also subjected to other tests. Other attributes triggering a termination 
failure included the attributes summarized in Table 1. Notice that a unique category was developed for 
liquids dispensed by injector—mechanical failure of the injecting mechanism. 
In short, 88 percent of the pharmaceutical lots in the SLEP study were extended beyond their original 
expiration date. The SLEP study supports the rather general conclusion that many pharmaceuticals can be 
extended beyond their expiration date. It further reveals the conclusion that pharmaceutical stability is 
dependent on manufacturer and can even vary from one manufacturing lot to another.  
NASA/TM—2016-218949 3 
TABLE 1.—SLEP TESTING, BASED ON PHARMACEUTICAL ATTRIBUTES. 
 
 
It is difficult to extrapolate the results of the SLEP study to a deep space mission. The environmental 
conditions of temperature and humidity during a deep space mission could be controlled and therefore 
could be comparable to storage conditions on Earth. However, a deep space mission occurs primarily 
outside of Earth’s magnetic field, an environmental condition not encountered in storage conditions on 
Earth. High CO2 concentrations in the spacecraft pose a unique environmental condition where enhanced 
diffusion of CO2 through packaging walls may be detrimental to select pharmaceuticals.  
Although the SLEP study does not specifically identify those pharmaceuticals that will survive the 
duration of a Mars mission while traversing the deep space environment, one could use the SLEP study as 
guide, where long-term storage on a deep space mission might be possible for those pharmaceuticals in 
the SLEP study that exhibit multiple shelf-life extensions. Mars missions requiring many years become 
problematic and may need to rely on new pharmaceutical formulations or resupply. Ideally, future work 
ought to include collecting durability data on specific pharmaceuticals intended for use during a Mars 
mission in a simulated or relevant environment. 
Samples and Data Returned From Orbiting Spacecraft 
Wotring conducted a retrospective study on medication use during spaceflights greater than 30 days, 
evaluating trends in usage (Ref. 6). Results were compared to shorter space shuttle mission records. The 
most frequently used item was sleep aids—zolpidem, zaleplon, or melatonin—used to address sleep 
difficulties brought about by the absence of circadian rhythm cues and occasional slam shifts to support 
mission activities. Back pain, muscle pain, and occasional headaches were most often treated with 
ibuprofen or acetaminophen. Promethazine was the preferred medication to address space adaptation 
syndrome. Efficacy was thought to be “somewhat to very effective” for all of these treatments. Two 
reports for rash treatments, thought to utilize an ointment—though not specifically identified as such—
were deemed “ineffective.” 
Du, et al., have conducted an investigation into 33 pharmaceutical products, 22 solids, 7 semisolid, 
and 4 liquid formulations, packaged in payload medication kits that were flown to, and returned from, ISS 
via the space shuttle (Ref. 1). Ground controls stored in an environmental chamber were available for 
comparison. Four payloads were returned after an on-orbit duration ranging from 13 to 880 days. 
Cumulative radiation dose during the 880 days was observed to be linear over time. Du, et al. found that 
“the number of formulations that did not meet content requirement of Active Pharmaceutical Ingredient 
(API) was higher in flight kits compared to the corresponding control kits from all four payloads” and the 
“difference in the number of unstable formulations between flight and control increased with the length of 
storage time in space.” 
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The pharmaceutical testing from Payload 1 revealed that no ground control samples exhibited 
physical changes and none failed the chemical potency test. Of the Payload 1 inflight pharmaceuticals, 
two semisolids were found to have physical changes, both discolorations, and another one failed the 
chemical potency test. In Payload 2, no ground control pharmaceuticals showed any physical changes and 
two pharmaceuticals failed the chemical potency test. Of the Payload 2 inflight pharmaceuticals, seven 
had signs of physical changes—six discolorations and one with some other physical change—and eleven 
failed the chemical potency requirement. Ground control pharmaceuticals from Payload 3 showed no 
physical changes, but the number of pharmaceuticals failing the chemical potency test increased to eight. 
Inflight pharmaceuticals from Payload 3 showed six with physical changes and 17 that failed the chemical 
potency test. In Payload 4, two control pharmaceuticals exhibited discoloration and liquefaction and 
16 control pharmaceuticals failed the chemical potency requirement. In Payload 4, six inflight 
pharmaceuticals showed signs of physical changes and 24 failed the chemical potency requirement. The 
ground control and inflight trends suggested ongoing physical changes with time. Decreasing chemical 
potency is observed in both ground control and inflight specimens, and the decrease in potency is more 
prevalent for the inflight specimens. 
One of the most degraded in both ground control and inflight specimens was clavulanate, suggesting 
it is “inherently unstable.” Degradation of amoxicillin was also observed, though the flight specimens 
dropped below 90 percent active pharmaceutical ingredient in the vicinity of 500 days consistent with the 
expiration date. Promethazine also exhibited degradation during space flight faster than in the ground 
control, with the injection version “reaching less than acceptable potency before the expiration date.” 
Atorvastatin and cefadroxil degraded more than two times faster in flight than on the ground. 
Trimethoprim and sulfamethoxazole exhibited similar behavior for flight and ground control. Du tempers 
these 880 day observations by indicating (with the exception of clavulanate) that “while degradation was 
faster in space than on the ground for most of the APIs, loss of API content was <20 percent of label 
claim except for levothyroxine and trimethoprim which were 28 and 21 percent, respectively.” In the 
context of a Mars mission, it should be noted that the pharmaceuticals from the Du study were stored on 
ISS, an environment within the Earth’s magnetic field. On a deep space mission, outside of the Earth’s 
magnetic field, degradation is likely to be more rapid varying with the stage of the solar cycle. Du also 
found “consistent with the general consensus on the ground that stability issues are less frequent with 
solid than liquid or semiliquid formulations.” 
Given the comparatively short duration of 880 days embedded within the eleven year solar cycle, one 
could approximate the radiation dose on ISS during the Du study as constant with time. The degradation 
in space-based pharmaceuticals above that observed in ground controls, at the molecular level, could then 
be considered as the random breaking of bonds in the active pharmaceutical ingredient by, for example, 
high energy protons. In the context of a Weibull distribution describing the so-called bathtub curve, the 
random degradation would represent the bottom of the bathtub curve where failure rate is neither 
decreasing (wearing in) nor increasing (wearing out), but staying the same, i.e., a shape factor of m = 1 
(Ref. 7). Of course, a more rigorous interpretation over the duration of the solar cycle could include the 
variation in high energy proton arrival and the corresponding variation in the breaking of molecular 
bonds. 
Picking clavulanate from the Du study, one can re-plot the flight degradation data in the context of a 
Weibull distribution to identify the time scale, Ɵ, and failure rate, λ. The summary is shown below in 
Figure 1. 
Clavulanate was selected here because it represents a worst case scenario based on the 
pharmaceuticals examined by Du. The failure rate is estimated to be 0.0026 per day. Another 
pharmaceutical from the Du study, ciprofloxacin is presented in Figure 2 utilizing a similar analysis. As 
can be seen, the time scale is necessarily longer and the failure rate is necessarily smaller because of the 
greater stability exhibited by the ciprofloxacin. It should be noted that the data are being extrapolated 
significantly in time, though the line passing through the four points at the far left appears to be a good fit 
to the eye. The failure rate for Ciprofloxacin is more than an order of magnitude less, at 0.00018 per day. 
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Figure 1.—Probability distribution function and time to failure for clavulanate, based on the work of Du, et al. 
(Ref. 1). 
 
 
 
 
Figure 2.—Probability distribution function and time to failure for ciprofloxacin, based on the work of Du, et al. 
(Ref. 1). 
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Follow-on experiments to the Du study need to be contemplated. One prospect to consider is to use an 
experimental design conducive to interpretation via Weibull statistics for the purpose of utilizing the 
failure rate results in predictive tools such as probabilistic risk assessment. Multiple long duration 
exposures in a deep space environment and multiple examples of each type of specimen would improve 
the failure rate statistics. Passive payloads of selected pharmaceutical specimens as part of sample return 
missions going beyond Earth’s magnetic field, such as returns from Mars or asteroids, could yield deep 
space exposures for pharmaceuticals of interest, and offer the prospect of identifying failure rate statistics 
based on multiple mission and multiple specimen post-flight analyses. 
Radiation 
One rudimentary path to consider is shielding pharmaceuticals from the radiation environment via 
robust storage. Rather than storing pharmaceuticals in a medical kit, it may be possible to shield the 
pharmaceuticals from high energy protons by protecting the supply of pharmaceuticals via ample use of 
aluminum shielding, where the storage unit for the pharmaceuticals is a purposely thick vault with 
suitable temperature and humidity controls inside. This path is problematic when trying to minimize 
overall mass, volume, and power. 
Another path being considered—with respect to human missions to Mars —is the use of multi-
purpose shield solutions. Simonsen reports for a human mission to Mars that “The Most Challenging 
Medical Standard To Meet For A Mars Mission Is That Associated With The Risk Of Radiation-induced 
Cancer (Ref. 8).” Radiation risk mitigation strategies currently under consideration include investing in 
innovative multi-purpose shield solutions—such as water filled composite shield sections and 
reconfigurable personal shielding—as well as biological countermeasures—using pharmaceuticals for 
repairing damaged DNA. Packaging of logistics around the habitat reduces radiation exposure and 
radiobiology countermeasures enable a living system to effect repairs. By analogy, pharmaceuticals stored 
in the habitat along with the astronauts would benefit from reduced radiation exposure. However, 
pharmaceuticals are inanimate by definition and cannot be repaired. The subject of pharmaceutical 
durability in a reduced space radiation environment during a Mars mission, en route and on the surface, 
remains of interest. 
Biological Samples at Cryogenic Temperatures, a Possible Mitigation Strategy  
This section introduces a possible way to mitigate radiation damage in pharmaceuticals carried on 
long duration missions. Considerable work has been done in the study of radiation chemistry since the 
1960s, and much of the work in ionizing radiation damage has emphasizes the cleavage of hydrogen 
bonds and the formation of free radicals. Energetic protons and the high-Z nuclei characteristic of space 
radiation impart damage via a Linear Energy Transfer mechanism. In general, the energy of ionizing 
radiation encountered in deep space is thought to be approximately 5 times more severe than in low Earth 
orbit (Ref. 9). 
One prospect is considered here for the purposes of discussion and future work. The literature 
suggests that biological specimens cooled to around 100 K can tolerate a significantly higher dose of 
radiation as delivered by an intense x-ray source during the process of x-ray crystallography of biological 
specimens. Cooling the specimen further results in a further reduction in radiation damage. Utilizing 
cubic insulin crystals as a model compound, Meents, et al., have shown that at 50 K, radiation damage to 
disulfide bridge structures is reduced by a factor of 4 compared to analogous observations at 100 K 
(Ref. 10). Extrapolating, one possible mitigation strategy to consider for future work is to purposely store 
pharmaceuticals at cryogenic temperatures for the purpose of increasing radiation durability. One could 
envision a cache of pharmaceuticals purposely delivered and stored cryogenically on the Martian surface 
prior to astronaut departure from Earth, and upon arrival, the pharmaceuticals could be reconstituted or 
warmed to room temperature for use, as needed. 
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The initial steps of such a future research effort could start by utilizing a model pharmaceutical 
compound rather than insulin. A beam line could facilitate exposures of the model compound to energetic 
protons, with an engineering emphasis placed on cooling the specimens while being illuminated. Post-
exposure analyses would reveal the extent that the active ingredient was maintained as a function of 
temperature. 
Conclusions 
The Pharmacology Risk Report by the Human Research Program discussed the problem of 
pharmaceutical durability in terms of risks and gaps. There exists a risk of therapeutic failure due to 
ineffectiveness of medication caused by exposure to deep space radiation and there exists a gap in 
understanding what the effect long-term spaceflight will have on drug stability. A study conducted by the 
Food and Drug Administration to evaluate pharmaceuticals stored beyond their original expiration date 
identified shelf life extensions for 88 percent of the pharmaceutical lots studied, based on assay and other 
observations. In general, solids received more extensions than gels or liquids. The Du study conducted on 
samples returned from ISS after in-space exposures of 13 to 880 days revealed that the number of 
formulations not meeting active pharmaceutical ingredient content requirements was higher for inflight 
samples compared to ground controls. Data from two products were re-plotted based on a Weibull 
distribution to identify their failure rates, opening the prospect of incorporating such data into 
probabilistic risk assessment models. Passive payloads of key pharmaceuticals as part of sample return 
missions conducted outside the Earth’s magnetic field offer the prospect of gathering long duration active 
pharmaceutical ingredient data in a relevant environment that could be used for failure rate calculations 
and modeling activities. Recent studies on innovative multi-purpose shield solutions, such as water filled 
composite shield sections, offer the prospect of reducing radiation exposure in a deep space habitat. One 
prospect for a mitigation strategy arises from observations made on insulin crystals, where cooling the 
specimen to 50 K reduces damage to disulfide bridge structures by a factor of 4 compared to analogous 
observations at 100 K. Initial steps toward future research include exposing selected pharmaceuticals to 
high energy protons, with an engineering emphasis on cooling the specimens. Perhaps one day, 
pharmaceuticals may be cached on the Martian surface and preserved cryogenically prior to astronaut 
departure from Earth. 
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